Utility of inflammatory makers, alanine aminotransferase, aspartate aminotransferase, and procalcitonin tests in COVID-19

Shkar Rzgar K.Rostam
Department of Biology, College of Science, University of Sulaimani, Iraq.
Khattab Ahmed Mustafa Shekhany
Department of Biology, College of Science, University of Sulaimani, Iraq.
Hardi Rafat Baqi Baqi
Department of Medical Laboratory Technology, Shaqlawa Technical College, Erbil Polytechnic University, Erbil, Iraq.
Share:

Abstract

Background and objective: Many tests are conducted for monitoring the progression and the severity of coronavirus disease (COVID-19) infection. However, the extent to which these tests are helpful in clinical practice and therapeutics of COVID-19 is still ambiguous. This study aimed to evaluate the feasibility of performing inflammatory marker tests, liver function tests, and procalcitonin test in the diagnosis and monitoring of COVID-19 infection.

Methods: The current study compares the results of alanine aminotransferase, aspartate aminotransferase, ferritin, and procalcitonin tests in two different populations of 123 COVID-19 suspects and a control group of 110 healthy individuals in Erbil city of Kurdistan region of Iraq to search for possible significant differences in both groups.

Results: The COVID-19 group had significantly higher ferritin and procalcitonin mean values than the control group (P = 0.001). The differences between alanine aminotransferase and aspartate aminotransferase were significant in some age and gender classes of both groups. However, the overall differences were not statistically significant (P = 0.339 and 0.286, respectively).

Conclusion: The outcome of the current study suggests that among the group of tests conducted for the study population, the most useful tests are ferritin and procalcitonin to monitor the COVID-19 patients' health status.

Metrics

Metrics Loading ...

References

  1. Worldometers. COVID-19 Coronavirus Pandemic 2020. (Accessed October 23, 2020, available at https://www.worldometers.info/coronavirus/
  2. WHO. Coronavirus disease (COVID19) 2020.(Accessed October 20, 2020, available at https://www.who.int/emergencies/diseases/novel coronavirus2019/question-and-answers-hub/qadetail/q-a-coronaviruses).
  3. Zeng F, Yuzhao H, Ying G, Mingzhu Y, Xiang C, Liang X, et al. Association of inflammatory markers with the severity of COVID-19 A meta-analysis. Int J Infect Dis. 2020;96:467–74. https://doi.org/10.1016/j.ijid.2020.05.055.
  4. Tay MZ, Poh CM, Rénia L, MacAry PA, LFP Ng. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–74. https://doi.org/10.1038/s41577-020-0311-8.
  5. Bertolini A, de Peppel IP, Frank AJA B, Han M, Alberto F, Fabio F, et al. Abnormal liver function tests in COVID-19 patients: relevance and potential pathogenesis. Hepatology. 2020;72(5):1864–72. https://doi.org/10.1002/hep.31480.
  6. Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. Int J Antimicrob Agents. 2020;56(2):106051. https://doi.org/10.1016/j.ijantimicag.2020.106051.
  7. Dennis J, McGovern A, Vollmer S, Mateen BA. Improving survival of critical care patients with Coronavirus Disease 2019 in England: A National Cohort Study, March to June 2020. Crit Care Med. 2021;49(2):209–14. https://doi.org/10.1097/CCM.0000000000004747.
  8. Beigel JH, Kay MT, Lori ED, Aneesh KM, Barry SZ, Andre CK, et al. Remdesivir for the treatment of Covid-19: Final Report. N Engl J Med. 2020;383:1813–26. https://doi.org/10.1056/NEJMoa200764.
  9. Salari N, Amin H, Rostam J, Aliakbar V, Shna R, Masoud M, et al. Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: A systematic review and meta-analysis. Global Health. 2020;16(1):57. https://doi.org/10.1186/s12992-020-00589-w.
  10. Vargas-Vargas M, Cortés-Rojo C. Ferritin levels and COVID-19. Rev Panam Salud Publica. 2020;44:e72. https://doi.org/10.26633/rpsp.2020.72.
  11. Zhou B, She J, Wang Y, Ma X. Utility of ferritin, procalcitonin, and C-reactive protein in severe patients with 2019 Novel Coronavirus Disease. Res Sq. 2020. https://doi.org/10.21203/rs.3.rs-18079/v1.
  12. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19) A meta-analysis. Clin Chim Acta. 2020;505:190–1. https://doi.org/10.1016/j.cca.2020.03.004.
  13. Ali N. Relationship between COVID-19 infection and liver injury. A review of recent data. Frontiers in Medicine 2020;7:458. https://doi.org/10.3389/fmed.2020.00458.
  14. Fan Z, Liping C, Jun L, Xin C, Jingmao Y, Cheng T, et al. Clinical features of COVID-19-related liver functional abnormality. Clin Gastroenterol Hepatol. 2020;18(7):1561–6. https://doi.org/10.1016/j.cgh.2020.04.002.
How to Cite
K.Rostam, S. R., Shekhany, K. A. M. ., & Baqi, H. R. B. (2022). Utility of inflammatory makers, alanine aminotransferase, aspartate aminotransferase, and procalcitonin tests in COVID-19. Zanco Journal of Medical Sciences (Zanco J Med Sci), 26(1), 22–28. https://doi.org/10.15218/zjms.2022.003

Send mail to Author


Send Cancel